NCT06631287View on ClinicalTrials.gov

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

PHASE3RecruitingINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

July 1, 2027

Conditions
Long COVIDSars-CoV-2 InfectionCoronavirus InfectionsCOVID-19
Interventions
DRUG

Baricitinib

4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.

OTHER

Placebo

Matched placebo capsule, PO once daily for 24 weeks.

Trial Locations (4)

30322

RECRUITING

Emory University, Atlanta

37203

RECRUITING

Vanderbilt University Medical, Nashville

55455

RECRUITING

University of Minnesota, Minneapolis

94143

RECRUITING

University of California San Francisco, San Francisco

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

Wes Ely

OTHER